Telemedicine, the use of telecommunications to deliver health services, expertise and information, is a promising but unproven tool for im proving the quality of diabetes care. We summarized the effectiveness of differ ent methods of telemedicine for the management of diabetes compared with usual care.
D
iabetes is one of the most common chronic diseases worldwide and is associated with premature death and disability. Over the past 3 decades, the prevalence of dia betes has more than doubled globally 1 and is projected to rise fur ther from 382 million in 2013 to 592 million in 2035. 2 Optimal gly cemic control helps to prevent and reduce complications of diabetes, including cardiovascular disease, kidney disease, blind ness, neuropathy and limb amputation. 3, 4 However, maintaining optimal glycemic control is challenging. 5 Telemedicine is the use of telecommunications to deliver health services, including interactive, consultative and diagnostic services. 6 Telemedicine interventions for diabetes can range from simple reminder systems via text messaging to complex Web inter faces through which patients can upload their glucose levels mea sured with a home meter and other pertinent data such as medica tions, dietary habits, activity level and medical history. Providers can review the data and provide feedback regarding medication adjustments and lifestyle modifications. Telemedicine has previ ously been shown to have clinical benefits for patients with severe asthma, 7 chronic obstructive pulmonary disease, 8 hypertension 9 or chronic heart failure. 10 It may also be helpful for providing care to people with diabetes, especially those unable to travel to health care facilities owing to large distances or disabilities. In particular, telemedicine may facilitate selfmanagement, an important po tential objective in diabetes care. 11, 12 Previous reviews describing the effect of telemedicine on the management of diabetes have been published. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] However, some focused on only specific types of telemedicine (e.g., telemonitor ing 20, 23, 26 ) or interventions delivered only by telephone.
METHODS:
We searched MEDLINE, Em base and the Cochrane Central Register of Controlled Trials databases (to Novem ber 2015) and reference lists of existing systematic reviews for randomized con trolled trials (RCTs) comparing telemedi cine with usual care for adults with diabe tes. Two independent reviewers selected the studies and assessed risk of bias in the studies. The primary outcome was glycated hemoglobin (HbA 1C ) reported at 3 time points (≤ 3 mo, 4-12 mo and > 12 mo). Other outcomes were quality of life, mortality and episodes of hypoglyce mia. Trials were pooled using random effects metaanalysis, and heterogeneity was quantified using the I 2 statistic. . Quantified heterogene ity (I 2 statistic) was 75%, 69% and 58%, re spectively. In metaregression analyses, the effect of telemedicine on HbA 1C ap peared greatest in trials with higher HbA 1C concentrations at baseline, in trials where providers used Web portals or text mes saging to communicate with patients and in trials where telemedicine facilitated medication adjustment. Telemedicine had no convincing effect on quality of life, mortality or hypoglycemia.
tional clinical trials have recently been published, which suggests the value of an updated review. We did a systematic review and quantitative synthesis of randomized controlled trials (RCTs) com paring the impact of different methods of telemedicine with usual care on glycated hemoglobin (HbA 1C ) and healthrelated quality of life in people with diabetes mellitus.
Methods
We performed a systematic review of RCTs that compared telemedi cine with usual care for the management of diabetes (type 1 and type 2). The review was reported according to an accepted guide line. 32 We followed a written but unregistered protocol.
We included studies if they were RCTs (parallel, cluster or cross over); were published in English; enrolled adult patients with diabe tes; compared telemedicine (some electronic form of providerto patient communication) with usual care; and reported the degree of metabolic control measured by HbA 1C level. We excluded studies on gestational diabetes because of the different nature of the disease. We considered peerreviewed fulltext articles published until November 2015.
Literature search
The search strategy was designed by an expert librarian. We searched the following electronic databases through the Ovid interface: MEDLINE (1946 ( -November 2015 , Embase (1974 -November 2015 and the Cochrane Central Register of Controlled Trials (November 2015). We also performed manual searches of the reference lists of existing systematic reviews. Because tele medicine is a broad term that can cover different interventions, we included all electronic forms of communication in our search. The search strategies are shown in Table A1 in Appendix 1 (available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.150885//DC1). Re sults of the search were transferred to Endnote software and were checked for duplicates.
Study selection
Two reviewers (N.W. and L.F.) independently screened the titles and abstracts of all unique citations. Studies with "diabetes," "type 1" or "type 2" in the title or abstract that studied any kind of telemedicine intervention were selected for fulltext review. Two independent reviewers (L.F. and a research assistant) assessed them using an inclusion/exclusion form based on a priori selection criteria for eligibility. Disagreements between the reviewers were resolved by meeting with a third reviewer (N.W.).
Data extraction
We used a standardized method to extract and record relevant properties of each trial into a database. Data from eligible trials were extracted by 1 reviewer (L.F.) and checked by another reviewer (Y.L.) using a standardized extraction sheet. We resolved disagreements by discussion.
We extracted the following information from selected studies: trial characteristics (study name, year of publication, country, study design, duration and sample size); patient characteristics (age, sex, type of diabetes, diabetes duration, blood pressure, cholesterol, body mass index [BMI] , smoking status and medications [insulin, oral hypoglycemic agents, lipidlowering therapy]); telemedicine interventions; and outcomes.
We classified the telemedicine interventions by (a) form of com munication from patient to provider, (b) form of communication from provider to patient, (c) type of provider (nurse, physician, allied health professional, clinical decision support system), (d) fre quency of contact and (e) characteristics of any intervention. Forms of communication between provider and patient included tele phone, smartphone application, email, text messaging (short mes sage service [SMS] ), Web portal (websites where patients upload blood glucose levels or other clinical data and share these with their health care providers, with or without providertopatient communication) and "smart" device or glucometer (any computer ized device specifically developed to collect and transmit patients' data to health care providers). Characteristics of any intervention included medication adjustment, exercise, general education about diabetes, blood pressure management and nutritional intervention.
Outcomes
The primary outcome was HbA 1C level. Secondary outcomes were quality of life as measured by a validated instrument, mortality and incidence of hypoglycemia. Hypoglycemic events were classified as severe if they were reported as such or if they required assistance.
Risk-of-bias assessment
We assessed risk of bias using the Cochrane Collaboration's tool 33 and included other items (funding, intention to treat and interim analysis) also known to be associated with bias. [34] [35] [36] [37] [38] [39] [40] Two reviewers (L.F. and a research assistant) assessed the trials independently and resolved any disagreements by meeting with a third reviewer (N.W.).
Data synthesis and analysis
We used Stata 13 (StataCorp) for all statistical analyses. We used the difference in means (MD) to pool continuous outcomes, and the risk ratio or the risk difference (when the events were rare) to pool dichotomous outcomes. Because of the differences expected between trials, we combined results using a randomeffects model. 41 We imputed missing standard deviations by substituting the baseline value from the same intervention group whenever possible; otherwise the median value from the systematic review was substituted. 42 We pooled outcomes using 3 categories of time points (≤ 3 mo, 4-12 mo and > 12 mo). Dichotomous outcomes of HbA 1C were pooled by the floored threshold value (e.g., < 6%, < 7%, < 8%, < 9%). We reported results from a qualityoflife instrument when data from at least 2 trials could be pooled. Heterogeneity was identified by visual inspection of the forest plots and by quantifying I 2 statistic. 43 We assessed publication bias using the Egger test 44 and by visual inspection of the contourenhanced funnel plot. 45 We planned a priori to examine the association between popu lation characteristics, intervention characteristics, riskofbias items (as specified earlier) and the effect of telemedicine on HbA 1C for characteristics reported in 5 or more trials. We did univariable weighted (with the inverse of the trial variance) linear metaregres sion to evaluate for effect modification on HbA 1C at 4-12 months.
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In a post hoc analysis, we examined whether adjustment for potential confounders in the triallevel results modified the effect of telemedicine on HbA 1C .
Results
Our literature search identified 3688 unique citations. After the screening of titles and abstracts, 517 potentially eligible studies were identified, of which 111 trials 21,47-156 met our inclusion criteria ( Figure  1 ). Disagreements occurred with 7% of the articles (κ value = 0.82).
Characteristics of the trials are summarized in Table 1 (see end of article). Of the 111 included trials, 4 were published before 2000. Five were cluster RCTs, 3 were crossover trials, and the remainder were parallel RCTs. Fortyone trials (37%) were done in the United States, 14 (13%) in Korea and 7 (6%) each in Canada and Australia; 6 or fewer were done in each of the remaining countries.
The median number of study participants was 114 (range 10-2378) ( Table 1 ). The median mean age at baseline was 56 years, and the median mean BMI at baseline was 31. The range of meta bolic control at baseline varied substantially between trials (mean HbA 1C 6.4%-10.9%); however, the mean HbA 1C level in 71 (64%) of the trials was 8% or greater at baseline.
The telemedicine interventions varied in a number of ways between the trials ( Table 2 [see end of article] ). Patients initiated com munication with their health care providers in 3 ways: voice, text mes saging and transmission of data. The trials used a large variety of plat forms: Web portal (24%), customized "smart" device (14%), telephone for communication to provider (13%), smartphone application (8%), SMS (5%), email (3%), personal digital assistant (2%), automated voice reminder system (1%), computer software (1%), fax (1%), list serv (electronic mailing list to send group emails; 1%), customized patientspecific Web page (1%) or a callme button (1%).
Health care providers initiated communication with patients in at least 4 ways: voice, text messaging, images and through clinical decision support systems. The platforms used were telephone (59%), clinical decision support system (32%; e.g., automated interactive voice [9%]), Web portal (22%), SMS (16%), email (7%), videoconference (4%), computer software (3%), customized "smart" device (3%), customized patientspecific Web page (2%), video message (2%), letter (2%), smartphone application (1%) or listserv (1%). Providers were nurses (37%), care managers (10%), diabetes educators (11%), physicians (29%), allied health profes sionals (17%; including dietitians, nutritionists, physiologists, exer cise trainers, psychologists and pharmacists), clinical decision sup port systems (32%) and nonspecialized support (23%; including trained peers, members of research teams, counsellors and com munity health care workers).
Most (94%) of the interventions were interactive, whereby the patient could communicate with the provider, and the provider could communicate with the patient. Interactive telecommunica tion initiated by providers occurred in the following frequencies: at least daily (8%), weekly (26%), every 2 weeks (10%), monthly (16%) or less often (7%). Frequency of interaction was not reported in 33% of trials. Many of the interventions (45%) adjusted medication based on the data received. Other frequent compo nents of the interventions included general diabetes education (76%), nutritional interventions (53%), exercise (49%) and blood pressure management (9%).
The riskofbias assessment of the trials is shown in Figure 2 and Table A2 in Appendix 1. Because blinding of participants is not feasible for telemedicine interventions, all trials were open label to the participants; thus, every trial included at least 1 element of risk of bias. However, we assessed for blinding of outcome assessors (present in 20% of trials). Seventyeight trials (70%) reported and described an appropriate method of randomization, but only 30 (27%) reported an adequate allocation concealment process. The intentiontotreat principle was applied in 51 (46%) of the trials. Public funding was exclusively used in 57 trials (51%).
Effect on HbA 1C
Thirtynine trials (n = 3165) reported the effect of telemedicine on HbA 1C at 3 months or less (Table 3 and Table A3 Citations screened n = 3688
Full-text articles assessed for eligibility n = 517 for which effects were larger than in the other trials. Exclusion of these 3 trials did not materially affect our results for the primary outcome (HbA 1C at 4-12 mo), but it did reduce heterogeneity (-0.24%, 95% CI -0.31% to -0.16%, I 2 = 58%). Findings were similar when control of HbA 1C was dichotomized at various thresholds (6.4%-6.5%, 7%-7.5%, 8% or 9%) and when we pooled results from the last time points from every available trial (Table A3 The contour funnel plot of HbA 1C was asymmetrical, consistent with publication bias (more small studies favouring telemedicine) (Figure 4) . The bias estimate from the regression analysis was signifi cant (Egger test: bias −0.95, p = 0.02). When the 3 outlier trials were removed, the bias estimate was not significant (bias −0.68, p = 0.07).
Meta-regression analysis
We explored a number of population and inter vention characteristics using univariable metaregression (Table 4 ). Both trial region and baseline HbA 1C modified the effect of telemedicine on final HbA 1C , but mean age, percent male, diabetes duration, BMI, insulin use, use of oral hypoglycemic therapy and diabetes type did not. European (n = 26) and North American trials (reference group, n = 47) reported simi lar MDs (difference in MD −0.08%, 95% CI −0.27% to 0.11%); however, trials from Asia (n = 9) reported significantly larger differences favour ing telemedicine relative to North American trials (difference in MD −0.49%, 95% CI −0.77% to −0.22%).
Because most telemedicine platforms were used in fewer than 5 trials, it was not possible to use metaregression to evaluate the rel ative merits of all platforms. Choice of patienttoprovider platform (smartphone application, Web portal, smart device, telephone) did not significantly modify the effect of telemedicine on HbA 1C . How ever, choice of providertopatient platform (SMS text messaging, Web portal, clinical decision support system, telephone) signifi cantly influenced the association between telemedicine and HbA 1C , with both SMS text messaging and Web portal associated with greater benefit than telephonebased systems (difference in MD: SMS v. telephone −0.28%, 95% CI −0.52% to −0.05%; Web portal v. telephone −0.35%, 95% CI −0.56% to −0.14%). Interventions in which providers adjusted medication in response to data from patients were also associated with larger improvements in HbA 1C (−0.23%, 95% CI −0.42% to −0.05%). Inclusion of interactive com munication, exercise, general diabetes education, blood pressure management or nutritional interventions did not modify the bene fit of telemedicine on HbA 1C . Frequency of contact and type of pro vider did not significantly modify the association.
None of the items from the Cochrane riskofbias tool were sig nificant effect modifiers, except for reporting loss to followup. Tri als that partially reported loss to followup (i.e., no stated reasons for loss to followup, or loss was reported for the whole trial and not by group) showed a smaller difference in HbA 1C than trials with fully reported loss to followup or trials that did not report loss to followup (difference in MD 0.30%, 95% CI 0.11% to 0.48%). Because there was no gradient of effect, there was no evidence that reporting versus not reporting loss to followup was a signifi cant effect modifier.
Effect on quality of life and mortality
Few trials (27 trials) reported on quality of life. Among the 23 trials that reported an instrument used by at least one other trial, a total of 6 instruments were validated ( nificant improvement in the Problem Areas in Diabetes score (MD at 4-12 mo: 2.86, 95% CI 1.74 to 3.97, I 2 = 0%, 2 trials, n = 363). Three scores or subscores showed significant worsening (SF36 physical functioning ≤ 3 mo: MD −3.98, 95% CI −0.62 to −7.34, I 2 = 30%, 2 trials, n = 311; SF36 social functioning ≤ 3 mo: MD −2.22, 95% CI −0.10 to −4.34, I 2 = 0%, 2 trials, n = 311; and EQ5D at 4-12 mo: MD −0.01, 95% CI −0.01 to −0.01, 2 trials, n = 743). There was no evidence of selective reporting of subscores for quality of life. However, the effect of telemedicine was not significant for most subscores, and the few statistically significant differences were likely not clinically relevant. 157 We pooled the mental health and physical health component summaries of the SF36 and SF12 instruments from 7 trials (n = 1333): MD 0.55 (95% CI −0.83 to 1.92; I 2 = 29%) and 0.06 (95% CI −1.01 to 1.13; I 2 = 0%), respectively. We also pooled the global scores (after transformation to a 1-100 range, where 100 was optimal) from all 3 diabetesspecific instruments from 8 trials (14 withintrial sub groups, n = 1324): MD 0.86 (95% CI −0.73 to 2.45; I 2 = 23%). Because all of these findings were nonsignificant, 157 there was no evidence to suggest that telemedicine enhanced quality of life.
Eleven trials (n = 1361) reported allcause mortality within 3 months, 42 trials (n = 7197) reported mortality at 4-12 months, and 4 trials (n = 2376) reported mortality beyond 12 months. The risk differences were all nonsignificant, without evidence of heteroge neity (≤ 3 mo: 0.2%, 95% CI −0.6% to 0.9%, I 2 = 0%, 6 deaths; 4-12 mo: −0.2%, 95% CI −0.6% to 0.2%, I 2 = 0%, 68 deaths; and > 12 mo: −0.3%, 95% CI −1.6% to 1.0%, I 2 = 0%, 351 deaths).
Effect on hypoglycemia
Five trials (n = 462) reported participants with hypoglycemic episodes within 3 months, and 4 trials (n = 282) reported participants with hypoglycemia at 4-12 months (Table 3) . One trial (n = 92) reported participants with severe hypoglycemia within 3 months, and 10 trials (n = 1259) reported participants with severe hypoglycemia at 4-12 months. There was no evidence that telemedicine reduced the risk of hypoglycemic episodes (risk difference for hypoglycemic episodes ≤ 3 mo: 0.0%, 95% CI −5.5% to 5.5%, I 2 = 63%; and at 4-12 mo: 3.1%, 95% CI −7.9% to 14.2%, I 2 = 47%). Risk differences for severe hypogly cemia were also not significant (≤ 3 mo: 0.0%, 95% CI −4.2% to 4.2%; and at 4-12 mo: −0.1%, 95% CI −1.0% to 0.8%, I 2 = 0%). 
Interpretation
Compared with usual care, the addition of telemedicine appeared to improve HbA 1C significantly in people with either type 1 or 2 dia betes. Although there was substantial heterogeneity, the pooled analyses showed that telemedicine lowered HbA 1C by 0.57% within 3 months and by 0.28% beyond 4 months. The lower apparent magnitude of benefit with longer followup may reflect reduced adherence to the intervention. Nonetheless, the effect on HbA 1C appears clinically relevant and is comparable to improvements associated with some oral antidiabetic agents (0.5%-1.25%), 158 psychosocial interventions (0.6%, 95% CI −1.2% to −0.1%) 159 or quality improvement strategies (0.42%, 95% CI 0.29% to 0.54%) 160 among patients with diabetes. However, we did not find good evi dence that telemedicine reduced the risk of hypoglycemia, quality of life or mortality, although it is unlikely that benefits for the latter would have been observed given the short duration of the included trials. Although telemedicine may also improve patient satisfaction with care, we did not collect data to test this hypothe sis, and thus this suggested benefit is speculative.
The metaregression analyses suggested that telemedicine inter ventions that facilitated medication adjustments were more effec tive in improving glycemic control than interventions that did not al low such adjustements. This finding is consistent with medication adjustment by nurse or pharmacist (0.23%, 95% CI 0.05% to 0.42%) reported in a previous metaregression analysis of quality improve ment strategies, including case man agement. 160 Our findings suggest that text messaging and Web portals may be especially effective mechanisms for linking providers to patients with dia betes. The use of SMS text messaging may be feasible to communicate and motivate patients, which could result in positive outcomes. 134 Although the trials we studied required providers to generate the text messages, it may prove feasible and less expensive to generate such messages by means of automated algorithms.
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There are various types of telemedi cine interventions, including telehealth (clinical services provided at a dis tance 6 ), telecare (often applied to non clinical aspects of care such as mobility and safety 27 ) and telemonitoring (re mote collection and transmission of clinical data from patients to provid ers 161 ). We primarily included trials in which patients received clinical feed back or communication from providers using some technology or devices. Therefore, we cannot differentiate trials that focused on telemonitoring or tele care in our review. Among the included trials, telemedicine interventions ranged from simple messages providing generic management sug gestions for patients 52, 134 to more comprehensive interventions per mitting videoconferencing with a nurse case manager, and remote monitoring of glucose and blood pressure with electronic data cap tured in the electronic medical record. 133 This wide variation in inter ventions likely contributed to some of the observed heterogeneity, which was only partly explained by metaregression.
Although our study is, to our knowledge, more comprehen sive than previous studies of telemedicine in diabetes, our re sults are generally consistent with prior work showing beneficial effects of telemedicine on HbA 1C . Compared with other system atic reviews, the relatively large number of studies that we iden tified allowed more detailed exploration of factors that may in fluence the magnitude of benefits on HbA 1C . We were also able to show that effects on HbA 1C diminished but were sustained over time and that benefits were more pronounced with more interac tive interventions (e.g., Web portals and text messaging).
Limitations
Weaknesses of our systematic review include limitations of the constituent trials (small sample size, lack of blinding and rela tively short duration). However, evidence suggests that lack of blinding would be less likely to affect an objectively assessed out come such as HbA 1C . 162 Second, there was considerable variation in the types of tele medicine technology used, the type of care the control groups This funnel plot appears mildly asymmetric about the vertical dashed line (the fixedeffects pooled esti mate). There are 3 statistical outliers that appear in the far right of the plot. The emptier left side of the inverted funnel may indicate small missing studies. Because most of these missing studies would be within the white region, they would be nonsignificant, which would indicate publication bias rather than some form of heterogeneity. received and the populations studied. The variation may have con tributed to the observed heterogeneity, and it may explain why some trials found positive effects of telemedicine and others found no benefit. However, we used metaregression to identify which types of telemedicine interventions were particularly efficacious. The potential benefits of SMS text messaging and Web portals when used in conjunction with tailored (patientspecific) sugges tions for medication adjustment suggest that these forms of inter vention should be the highest priority for future uptake.
Third, as with all metaregression analyses using summary data rather than individual participant data, our findings are vulnerable to the ecological fallacy (i.e., findings at the population level do not always translate correctly to individuals) and from limited sta tistical power.
Fourth, we did not collect data on the effects of telemedicine on satisfaction of care or its costeffectiveness. 163 Finally, we found some evidence of publication bias, which sug gests that some small negative trials might exist, but they were not 
Risk of bias
Randomization identified by our literature search. If this supposition were correct, it might lead to a slight overestimation of the efficacy of telemedicine interventions, but it would likely not affect our conclusion given that elimination of the outliers removed any significant publication bias.
Conclusion
Our systematic review showed that telemedicine may be a useful supplement to usual clinical care to control HbA 1C , at least in the short term. Telemedicine interventions appeared to be most effec tive when they use a more interactive format, such as a Web portal or text messaging, to help patients with selfmanagement. Note: CDSS = clinical decision support system, NA = not applicable, PCP = primary care provider, PDA = personal digital assistant, SMS = short message service (text messaging), "-" = not reported. *Studies are ordered by providertopatient communication; they are ordered by any use of Web portals, SMS text messaging, automated communication, smart device, computer software, videoconference, email, customized patient Web pages, video messaging, smartphone application, telephone and letter. A smart device is any computerized device specifically developed to collect and transmit patient data to health care providers. Web portals are websites where patients upload blood glucose or other clinical data and share these with their health care providers; many times providers also use Web portals to provide feedback to patients. CDSS systems receive data from patients and automatically respond using computer algorithms in a variety of ways, such as precomposed messages sent as SMS text messages to patients (Kim 2010 95 ), alarms sent to the providers when abnormal data are received (Gomez 78 ), analyzed data reports sent to providers (Quinn 125 ) and voice feedback over the telephone to patients (Schillinger 131 ). Other components not mentioned in this table include psychological support, such as support for depression, smoking cessation and behavioural therapy. †Indicates an approximate frequency of feedback. For example, we used "~ daily" rather than 3 times per week for Lim 102 ; "~ every 2 wk" replaced 14 times per 6 months for Eakin, 67 and 11 times per 6 months for Munshi; 112 "~ monthly" replaced 5 times per 6 months for Blackberry 55 and Frosch, 73 and 10 times per year for Walker; 147 and "~ every 2 mo" replaced every 7 weeks for Young. 155 
